A phase 1 and 2 clinical trial of an experimental vaccine against the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, known as MV-CHIKV, is a recombinant live-attenuated measles vaccine virus expressing chikungunya proteins that induce antibody production.
Jeff Lyon. Chikungunya Vaccine Trials Begin. JAMA. 2017;318(4):322. doi:10.1001/jama.2017.8753